Article

Prostate cancer found in 15% of men with 'normal' PSA, DREs

Men who have a low PSA level according to standard PSA testing can still have prostate cancer, according to a recent study in the New England Journal of Medicine (2004; 350:2239-46).

Related Videos
Raveen Syan, MD, FPMRS, answers a question during a video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Timothy Lyon, MD, answers a question during a video interview
Related Content
Medicine doctor hand working with modern digital tablet computer interface as medical network concept | © NINENII - stock.adobe.com
January 24th 2025

How to bill for placement of a peri-rectal spacer

Jonathan Rubenstein, MD Mark Painter
"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Urogynecology for the Advanced Practice Provider
January 24th 2025

Urogynecology for the Advanced Practice Provider

American Urogynecologic Society
Join AUGS in Nashville, TN, or virtually, April 24-26 for this annual course!
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke
64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.
Standard pathology reports may be difficult to understand for patients with prostate cancer
January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.